Comparison of dopamine and norepinephrine in shock.
Romero
Carlos M
CM
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D004298:Dopamine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009638:Norepinephrine / Q000009:adverse effects / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy; D012770:Shock, Cardiogenic / Q000188:drug therapy / Q000401:mortality; D012772:Shock, Septic / Q000628:therapy*; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014662:Vasoconstrictor Agents; D004298:Dopamine; D009638:Norepinephrine